DNA Diagnostics Market

The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period. Growth in the DNA diagnostics market is primarily driven by the growing burden of genetic and infectious diseases, which has created a significant demand for accurate and efficient diagnostic tools. Additionally, the increasing availability of funding for R&D activities has fuelled advancements in technology, enabling the development of innovative DNA diagnostic solutions.

The DNA diagnostics market is highly consolidated, with top companies holding significant market shares. The top three players in this market include Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland). Players in this market are focusing on adopting organic and inorganic growth strategies such as DNA diagnostic product launches, expansions, acquisitions, agreements, and partnerships to increase their DNA diagnostics offerings, cater to customer needs, increase their profitability and expand their presence in the global DNA diagnostics market.

To know about the assumptions considered for the study download the pdf brochure

ILLUMINA INC. (US)

Illumina Inc. accounts for the largest share of the DNA diagnostics market in 2023. It is a leading provider of sequencing and array-based solutions for genetic and genomic analysis. Develops, manufactures, and markets integrated systems to analyze genetic variations and biological functions. Its portfolio includes integrated systems, consumables, and analysis tools to simplify genetic analysis. The company also offers software and informatics platforms, including cloud-based computational tools, for sequencing and array-based systems. The company operates through two major business segments, namely, Core Illumina, and GRAIL. Both segments cater to the diagnostics market. Furthermore, Illumina's substantial investment in research and development drives continuous innovation, ensuring that it remains a leader in the rapidly evolving field of genomics.

Danaher Corporation (US)

Danaher Corporation held the second-largest share of the DNA diagnostics market in 2023. It manufactures and commercializes medical, industrial, and commercial products and services. The company operates through three business segments: Life Sciences, Diagnostics, and Biotechnology. The Diagnostics segment offers a wide range of molecular-based analytical instruments, reagents, consumables, software, and services used for DNA tests. Danaher's extensive network of approximately 242 manufacturing and distribution facilities worldwide is a pivotal cornerstone of the company's success.

F. HOFFMANN-LA ROCHE LTD. (Switzerland)

F. Hoffmann-La Roche Ltd. (Switzerland) held the third-largest share of the DNA diagnostics market in 2023. It is an established and research-driven healthcare firm that operates through two business segments, namely, the Pharmaceutical Division and the Diagnostics Division. The company offers numerous diagnostic products for HPV infection, hepatitis, HIV, diabetes, blood coagulation, and fertility, all of which are prominently used by hospitals, reference laboratories, patients, researchers, and physicians. The company operates in the DNA diagnostics market through its diagnostics division. Additionally, the company's commitment to innovation and quality has solidified its reputation as a trusted provider in the DNA diagnostics field, continually driving advancements and setting industry standards.

Related Reports:

DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]